NCT07406282 2026-04-09
Double-DARE
Bayer
Recruiting
Clinical Trials
14 trialsNCT02125617 2026-01-14
uPARCRPC
Rigshospitalet, Denmark
Terminated
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT07181122 2025-11-24
PRO-MIND
Ankara Etlik City Hospital
Recruiting
NCT06151418 2025-06-04
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Pfizer
Completed
NCT06652607 2025-03-12
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT02608359 2025-02-03
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
Johnson & Johnson Private Limited
Withdrawn
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT06473259 2024-06-25
ECHOS
Santa Chiara Hospital
Recruiting
NCT06430411 2024-05-28
OLIGOMET
Medical University of Vienna
Not yet recruiting
NCT02353715 2020-12-24
PEAX
Duke University
Completed
NCT02364531 2019-12-06
COSMiC
Janssen Inc.
Completed
NCT03325127 2018-10-31
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Bayer
Withdrawn
NCT01692483 2015-12-02
Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Janssen Pharmaceutica
Withdrawn